Epitope mapping combined with the knowledge on the binding orientation of reductase in the predictive aromatase-reductase complex provide insights into understanding why MCA 677 is a good antibody in the detection of aromatase in breast cancer tissues. The gene discussed is CYP19A1; the disease is breast carcinoma.